Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma

Next Previous
Trial Profile

Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maplirpacept (Primary) ; Azacitidine; Azacitidine; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Isatuximab; Nivolumab; Pembrolizumab; Rituximab; Venetoclax
  • Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Erdheim-Chester disease; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TTI-622-01
  • Sponsors Pfizer; Trillium Therapeutics Inc

Most Recent Events

  • 02 Sep 2024 Status changed from active, no longer recruiting to discontinued.
  • 21 Dec 2023 Planned End Date changed from 25 Mar 2025 to 11 Sep 2024.
  • 21 Dec 2023 Planned primary completion date changed from 25 Mar 2024 to 11 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top